文献速递妇科

奥拉帕利维持治疗新诊断晚期卵巢癌BRCA突变患者:SOLO1中国队列

Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation: SOLO1 China cohort.
PubMed 文献 · Gynecol Oncol · 2020-11-27

SOLO1中国队列纳入64例新诊断晚期卵巢癌BRCA突变患者,按2:1随机接受奥拉帕利(300mg每日两次)或安慰剂维持治疗。奥拉帕利较安慰剂降低疾病进展或死亡风险54%(HR 0.46,95%CI 0.23-0.97),中位PFS奥拉帕利组未达到、安慰剂组9.3个月。常见不良事件为恶心、贫血和白细胞减少,支持奥拉帕利在中国患者中的维持治疗应用。

要点

  • 奥拉帕利降低BRCA突变晚期卵巢癌进展或死亡风险54%(HR 0.46)。
  • 中位PFS奥拉帕利组未达到,安慰剂组9.3个月。
  • 常见不良事件为恶心、贫血、白细胞减少,≥3级不良事件奥拉帕利组56.8%。

核心结论

  • SOLO1中国队列结果支持奥拉帕利用于中国新诊断晚期卵巢癌BRCA突变且铂类化疗后完全或部分缓解患者的维持治疗。

研究设计与样本

  • 双盲、多中心研究,64例患者按2:1随机接受口服奥拉帕利片300mg每日两次或安慰剂。

主要发现

  • 奥拉帕利组44例、安慰剂组20例;奥拉帕利降低疾病进展或死亡风险54%(HR 0.46,95%CI 0.23-0.97)。
  • 中位PFS奥拉帕利组未达到,安慰剂组9.3个月。
  • 奥拉帕利组常见不良事件为恶心(63.6% vs 安慰剂25.0%)、贫血(59.1% vs 15.0%)、白细胞减少(54.5% vs 20.0%)。
  • ≥3级不良事件发生率奥拉帕利组56.8%,安慰剂组30.0%。

关键数值与推荐

  • 主要终点为研究者评估的PFS(改良RECIST v1.1)。

临床怎么用

  • 对于中国新诊断晚期卵巢癌BRCA突变且铂类化疗后完全或部分缓解的患者,可考虑奥拉帕利维持治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Maintenance therapy with the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib provided a substantial progression-free survival (PFS) benefit compared with placebo in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (BRCAm) who were in clinical complete or partial response following platinum-based chemotherapy in the Phase III SOLO1 global study. This led to the approval of maintenance olaparib in China, USA, EU, Japan and other countries, in the newly diagnosed setting. This separate China cohort of the SOLO1 study investigated the efficacy and safety of maintenance olaparib within the Chinese population. PATIENTS AND METHODS: In this double-blind, multicentre study, patients were randomized 2:1 to receive oral olaparib tablets (300 mg twice daily) or placebo. The primary endpoint was investigator-assessed PFS (modified RECIST v1.1). RESULTS: Of the 64 randomized patients, 44 received olaparib and 20 placebo. Olaparib reduced the risk of disease progression or death by 54% compared with placebo (HR 0.46, 95% Cl 0.23-0.97; median PFS was not reached in the olaparib arm vs 9.3 months in the placebo arm). The most common AEs in the olaparib arm were nausea (63.6 vs 25.0% with placebo), anaemia (59.1 vs 15.0%) and leukopenia (54.5 vs 20.0%). Grade ≥3 AEs were experienced by 56.8% of olaparib patients and 30.0% of placebo patients. CONCLUSIONS: Results in the SOLO1 China cohort support the use of olaparib as maintenance treatment for Chinese patients with newly diagnosed advanced ovarian cancer who have a BRCAm and are in complete or partial response after platinum-based chemotherapy.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Wu L, Zhu J, Yin R, et al. Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation: SOLO1 China cohort. Gynecol Oncol. 2020. PMID: 33250205. doi:10.1016/j.ygyno.2020.10.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。